» Articles » PMID: 28328090

Bronchiolitis Score of Sant Joan De Déu: BROSJOD Score, Validation and Usefulness

Overview
Date 2017 Mar 23
PMID 28328090
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To validate the bronchiolitis score of Sant Joan de Déu (BROSJOD) and to examine the previously defined scoring cutoff.

Patients And Methods: Prospective, observational study. BROSJOD scoring was done by two independent physicians (at admission, 24 and 48 hr). Internal consistency of the score was assessed using Cronbach's α. To determine inter-rater reliability, the concordance correlation coefficient estimated as an intraclass correlation coefficient (CCC) and limits of agreement estimated as the 90% total deviation index (TDI) were estimated. An expert opinion was used to classify patients according to clinical severity. A validity analysis was conducted comparing the 3-level classification score to that expert opinion. Volume under the surface (VUS), predictive values, and probability of correct classification (PCC) were measured to assess discriminant validity.

Results: About 112 patients were recruited, 62 of them (55.4%) males. Median age: 52.5 days (IQR: 32.75-115.25). The admission Cronbach's α was 0.77 (CI95%: 0.71; 0.82) and at 24 hr it was 0.65 (CI95%: 0.48; 0.7). The inter-rater reliability analysis was: CCC at admission 0.96 (95%CI 0.94-0.97), at 24 h 0.77 (95%CI 0.65-0.86), and at 48 hr 0.94 (95%CI 0.94-0.97); TDI 90%: 1.6, 2.9, and 1.57, respectively. The discriminant validity at admission: VUS of 0.8 (95%CI 0.70-0.90), at 24 h 0.92 (95%CI 0.85-0.99), and at 48 hr 0.93 (95%CI 0.87-0.99). The predictive values and PCC values were within 38-100% depending on the level of clinical severity.

Conclusion: There is a high inter-rater reliability, showing the BROSJOD score to be reliable and valid, even when different observers apply it. Pediatr Pulmonol. 2017;52:533-539. © 2016 Wiley Periodicals, Inc.

Citing Articles

Reduced antiviral gene expression and elevated CXCL8 expression in peripheral blood are associated with severe hypoxemia in RSV-infected children.

Pita-Martinez C, Goez-Sanz C, Virseda-Berdices A, Gonzalez-Praetorius A, Mazario-Martin E, Rodriguez-Mesa M Front Immunol. 2024; 15:1438630.

PMID: 39403383 PMC: 11472821. DOI: 10.3389/fimmu.2024.1438630.


Clinical-Ultrasound Model to Predict the Clinical Course in Bronchiolitis.

Rodriguez Garcia L, Hierro Delgado E, Oulego Erroz I, Rey Galan C, Mayordomo Colunga J Children (Basel). 2024; 11(8).

PMID: 39201922 PMC: 11352824. DOI: 10.3390/children11080987.


Impact of universal immunization program with monoclonal antibody nirsevimab on reducing the burden of serious bronchiolitis that need pediatric intensive care.

Alejandre C, Penela-Sanchez D, Alsina J, Aguera M, Soler A, Moussalam S Eur J Pediatr. 2024; 183(9):3897-3904.

PMID: 38910199 DOI: 10.1007/s00431-024-05634-z.


Respiratory Syncytial Virus-Associated Deaths among Children under Five before and during the COVID-19 Pandemic in Bangladesh.

Hassan M, Islam M, Haider S, Shirin T, Chowdhury F Viruses. 2024; 16(1).

PMID: 38257812 PMC: 10818674. DOI: 10.3390/v16010111.


Comparison of Easy-to-Use Bronchiolitis Scores in the Post-COVID-19 Era-An Observational Study.

Martin-Latorre M, Martinez-Campos L, Martin-Gonzalez M, Castro-Luna G, Lozano-Paniagua D, Nievas-Soriano B Children (Basel). 2023; 10(12).

PMID: 38136036 PMC: 10742179. DOI: 10.3390/children10121834.